News | December 27, 2025
Symbiosis rolls out first 10,000 vial batch at Stirling Facility
This production milestone positions Symbiosis at the forefront of meeting rising global demand for life-saving medicines
This production milestone positions Symbiosis at the forefront of meeting rising global demand for life-saving medicines
According to IQVIA sales data for the 12-month period ending October 2025, the Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) market2 achieved annual sales of approximately $67.6 million
Glenmark's Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug
Patients can now get the starting 2.5 mg dose for $299 per month
Glenmark will begin distribution in November 2025
Trastuzumab Deruxtecan 100mg/5mL vial lyophilized powder for concentrate for solution for infusion is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors
According to IQVIA sales data for the 12-month period ending June 2025, the Mycamine for Injection, 50 mg/vial and 100 mg/vial market achieved annual sales of approximately $60.7 million
The projected business potential is around US$ 1 million in the first year
The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), KENGREAL of Chiesi USA
Glucagon is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus
Subscribe To Our Newsletter & Stay Updated
